NCT00964418View on ClinicalTrials.gov

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days

DRUG

insulin glargine

0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days

Trial Locations (1)

8036

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY